Congenital Heart DiseaseTrends in Pulmonary Valve Replacement in Children and Adults With Tetralogy of Fallot
Section snippets
Methods
The Pediatric Health Information Systems (PHIS) database is an administrative database that contains data from inpatient, emergency department, ambulatory surgery, and observation encounters from 43 not-for-profit, tertiary care pediatric hospitals in the United States, affiliated with the Children’s Hospital Association (Overland Park, Kansas).1 Data quality and reliability are assured through a joint effort between the Children’s Hospital Association and participating hospitals. The PHIS data
Results
From 2004 to 2012, a total of 799 subjects with TOF underwent PVR at 35 centers across the United States contributing data to the PHIS database (Table 1). Eight centers (10 subjects) did not meet the inclusion criteria and were excluded. Median age at PVR was 17 years (range 10 to 64). Most of the population was male (57%) and white (75%). A small minority (10%) carried diagnoses of genetic syndromes. Median hospital LOS was 4 days (range 1 to 126), with a median duration of ICU stay 2 days
Discussion
In this observational study from 35 children’s hospitals in the United States, the annual number of PVRs in children and adults with TOF increased significantly over 9 years. Although the age of subjects who underwent PVR did not change significantly, there was also significant heterogeneity among centers in the age at which patients underwent PVR. Older age was associated with increased ICU duration and cost. Presence of a genetic syndrome was associated with younger age at PVR, longer
Acknowledgment
The authors thank Zeinab Mohammad for assistance in data extraction and A. Russell Localio, PhD, for consultation during statistical analysis.
References (30)
- et al.
Late pulmonary valve replacement after repair of tetralogy of Fallot
J Thorac Cardiovasc Surg
(2001) - et al.
Effects of pulmonary valve replacement on QRS duration and right ventricular cavity size late after repair of right ventricular outflow tract obstruction
Am J Cardiol
(2005) - et al.
Pulmonary valve replacement after operative repair of tetralogy of Fallot: meta-analysis and meta-regression of 3,118 patients from 48 studies
J Am Coll Cardiol
(2013) - et al.
Effect of pulmonary valve replacement on left ventricular function in patients with tetralogy of Fallot
Am J Cardiol
(2012) - et al.
Predicting outcome of pulmonary valve replacement in adult tetralogy of Fallot patients
Ann Thorac Surg
(2007) - et al.
Homograft insertion for pulmonary regurgitation after repair of tetralogy of Fallot improves cardiorespiratory exercise performance
Am J Cardiol
(2000) - et al.
Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study
Lancet
(2000) - et al.
Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair
Am J Cardiol
(2005) - et al.
Timing and technique of pulmonary valve replacement in the patient with tetralogy of Fallot
Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu
(2012) - et al.
Late Complications of repair of tetralogy of Fallot and Indications for pulmonary valve replacement
Semin Thorac Cardiovasc Surg
(2005)
Meta-analysis of pulmonary valve replacement after operative repair of tetralogy of Fallot
Am J Cardiol
22q11.2 Deletion syndrome is associated with perioperative outcome in tetralogy of Fallot
J Thorac Cardiovasc Surg
22q11.2 Deletion syndrome is associated with increased perioperative events and more complicated postoperative course in infants undergoing infant operative correction of truncus arteriosus communis or interrupted aortic arch
J Thorac Cardiovasc Surg
Cost analysis of percutaneous pulmonary valve replacement
Am J Cardiol
Adults or big kids: what is the ideal clinical environment for management of grown-up patients with congenital heart disease?
Ann Thorac Surg
Cited by (0)
Dr. O’Byrne receives support from the National Institutes of Health (NIH) (Grant T32 HL007915) and an Entelligence Young Investigator grant. Dr. Mercer-Rosa receives support from the NIH (Grant NIH 3U01HL098153-03S1). Dr. Kawut is supported by the NIH (Grant K24 HL103844).
See page 123 for disclosure information.